Table 1.
Characteristic | Value |
---|---|
Age, yr | 57.7 (31–82) |
Dose of fulvestrant | |
250 mg | 24 (29) |
500 mg | 60 (71) |
Initial stage of breast cancer | |
Stage I–III | 67 (80) |
Stage IV | 17 (20) |
No. of previous endocrine therapy | |
1 | 18 (21.4) |
2 | 43 (51.2) |
3 | 22 (26.2) |
4 | 1 (1.2) |
Median (range) | 2 (1–4) |
No. of previous chemotherapy | |
0 | 39 (46.3) |
1 | 15 (17.8) |
2 | 11 (13.1) |
3 | 6 (7.1) |
4 | 4 (4.8) |
≥ 5 | 9 (10.7) |
Median (range) | 2 (0–11) |
Adjuvant endocrine treatment (n = 67) | |
Yes | 53 (79.1) |
No | 14 (20.9) |
Disease extent | |
Visceral metastasis | 49 (58.3)a |
Lung | 34 |
Liver | 16 |
Brain | 4 |
Bone marrow | 4 |
Adrenal gland | 4 |
Other (pancreas, kidney, ovary) | 5 |
Non-visceral metastasis | 35 (41.7) |
Bone only | 17 |
Bone and nodes | 11 |
Soft tissue | 7 |
Tumor response to fulvestrant | |
Complete response | 0 |
Partial response | 13 (15.5) |
Stable disease | 21 (25.0) |
Progressive disease | 50 (59.5) |
Disease control rate | 34 (40.5) |
95% Confidence interval | 30.5–51.5 |
Values are presented as median (range) or number (%).
Among them, 10 patients had multiple visceral involvement.